Fred Alger Management’s Soleno Therapeutics SLNO Stock Holding History

Fred Alger Management’s Portfolio SLNO Stock Details SLNO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-28,215	Closed	-$945K	–	490
2026 Q1	$945K	Sell	28,215 -264	-0.9%	-$10.3K	﹤0.01%	360
2025 Q4	$1.32M	Sell	28,479 -14	-0%	-$768	0.01%	340
2025 Q3	$1.93M	Sell	28,493 -14,398	-34%	-$1.07M	0.01%	324
2025 Q2	$3.59M	Buy	42,891 +2,497	+6%	+$187K	0.02%	270
2025 Q1	$2.89M	Buy	40,394 +25,589	+173%	+$1.25M	0.02%	279
2024 Q4	$665K	Buy	14,805 +8,660	+141%	+$449K	﹤0.01%	377
2024 Q3	$310K	Buy	+6,145	New	+$294K	﹤0.01%	394

Fred Alger Management's SLNO Position: Q2 2026 in Review

Fred Alger Management sold out of Soleno Therapeutics (SLNO) in Q2 2026, closing a stake of 28,215 shares — an estimated $945K sold.

Fred Alger Management first reported a position in SLNO in Q3 2024 and held it in 7 quarters. The position peaked at $3.59M in Q2 2025. 0 funds tracked by Wall St. Rank hold SLNO as of Q2 2026.

Fred Alger Management reported no remaining Soleno Therapeutics position as of Q2 2026 after selling out during the quarter.
Fred Alger Management sold 28,215 Soleno Therapeutics shares in Q2 2026, an estimated $945K.
Fred Alger Management first reported a position in Soleno Therapeutics in Q3 2024 and held it in 7 quarters.
Fred Alger Management's Soleno Therapeutics position peaked at $3.59M in Q2 2025.
0 funds tracked by Wall St. Rank held Soleno Therapeutics as of Q2 2026.

Based on Fred Alger Management's 13F filing for Q2 2026, filed 14 Aug 2026.